Immune-Mediated Arthritis

Immune-mediated arthritis (IMA) encompasses a group of inflammatory joint diseases in dogs and cats characterized by synovial inflammation driven by an aberrant immune response. These conditions are classified into erosive and non-erosive forms based on radiographic and pathologic findings. Erosive immune-mediated arthritis includes rheumatoid arthritis (RA) and feline chronic progressive polyarthritis (FCPP), while non-erosive forms include systemic lupus erythematosus (SLE)-associated arthritis, polyarthritis of greyhounds, and reactive polyarthritis. The disease process involves immune complex deposition, autoantibody production, and cellular infiltration of the synovium, leading to synovitis, pannus formation, cartilage degradation, and in erosive forms, subchondral bone erosion. Surgical intervention is rarely curative but may be indicated for synovectomy, arthrodesis, or joint replacement in end-stage disease. Medical management with immunosuppressive agents remains the cornerstone of therapy.

The exact etiology of immune-mediated arthritis is often idiopathic, but several mechanisms are implicated. Type III hypersensitivity reactions involve immune complex deposition in synovial capillaries, activating complement and attracting neutrophils. Autoantibodies, such as rheumatoid factor (RF) and antinuclear antibodies (ANA), target self-antigens. In infectious triggers, molecular mimicry or bystander activation may occur following bacterial, viral, or parasitic infections. In dogs, polyarthritis may be associated with bacterial endocarditis, borreliosis, ehrlichiosis, or leishmaniasis. In cats, FCPP is linked to feline leukemia virus (FeLV) and feline syncytium-forming virus (FeSFV) infections. Drug-induced immune-mediated arthritis has been reported with sulfonamides, penicillins, and cephalosporins. Vaccination has been implicated as a trigger in some cases. Genetic predisposition is suggested in certain breeds, such as the greyhound, where a specific non-erosive polyarthritis is recognized.

Immune-mediated arthritis is relatively uncommon in small animal practice, accounting for less than 1% of joint diseases. It predominantly affects dogs, with a higher incidence in medium to large breeds. Erosive rheumatoid arthritis is rare, typically affecting middle-aged to older dogs (4-8 years), with a slight female predisposition. Non-erosive immune-mediated polyarthritis is more common and can occur in any breed, but certain breeds like the greyhound, Shetland sheepdog, and spaniels may be overrepresented. Feline chronic progressive polyarthritis is seen in young to middle-aged cats, often with a history of FeLV or FeSFV infection. There is no strong sex predilection. Working dogs may be at higher risk due to increased exposure to infectious agents and environmental triggers.

The pathophysiology of immune-mediated arthritis involves a complex interplay of humoral and cell-mediated immunity. In type III hypersensitivity, circulating immune complexes deposit in the synovial microvasculature, leading to complement activation (C3a, C5a) and neutrophil chemotaxis. Neutrophils release proteolytic enzymes, reactive oxygen species, and pro-inflammatory cytokines (IL-1, TNF-α), causing synovial hyperplasia, angiogenesis, and pannus formation. Pannus, a granulation tissue rich in inflammatory cells, invades the articular cartilage and subchondral bone, leading to erosions. In erosive forms, there is progressive destruction of cartilage and bone, resulting in joint deformity and ankylosis. In non-erosive forms, inflammation is primarily confined to the synovium, with minimal cartilage damage. Autoantibodies, such as RF (IgM against IgG) and ANA, contribute to immune complex formation. T cells, particularly Th1 and Th17 subsets, play a role in sustaining inflammation. The synovial fluid becomes turbid, with increased neutrophil counts and decreased viscosity.

Intrinsic factors include genetic susceptibility, as certain breeds have a higher incidence. Age and sex may influence disease expression, with middle-aged females more commonly affected in RA. Metabolic factors such as obesity can exacerbate joint stress and inflammation. Extrinsic factors include infectious agents (bacterial, viral, parasitic), which may trigger the immune response. Drug administration, particularly antibiotics and vaccines, can precipitate immune-mediated arthritis. Environmental stress, such as trauma or surgery, may also act as a trigger. Prior joint disease or surgery can lead to immune dysregulation. In cats, retroviral infections (FeLV, FeSFV) are significant risk factors for FCPP.

Clinical signs of immune-mediated arthritis are typically polyarticular, with stiffness, lameness, and joint swelling affecting multiple joints, often symmetrically. Affected joints are painful on palpation, with reduced range of motion. Dogs may exhibit a 'bunny-hopping' gait or reluctance to move. Systemic signs include fever, lethargy, anorexia, and weight loss. In erosive forms, joint deformity and crepitus may be evident. In non-erosive forms, signs may be intermittent. Cats with FCPP may show severe lameness, joint swelling, and fever. Physical examination may reveal joint effusion, synovial thickening, and muscle atrophy. In SLE, additional signs such as skin lesions, glomerulonephritis, and hemolytic anemia may be present.

Differential diagnoses include septic arthritis, degenerative joint disease (osteoarthritis), trauma-induced arthritis, and neoplasia (e.g., synovial cell sarcoma). Septic arthritis typically presents with acute severe lameness, joint swelling, and fever, and is confirmed by synovial fluid culture and cytology showing degenerate neutrophils and bacteria. Osteoarthritis is usually non-inflammatory, with chronic progressive lameness and radiographic evidence of osteophytes. Trauma may cause hemarthrosis, with a history of injury. Synovial cell sarcoma is a rare neoplasm that can mimic arthritis, but imaging and biopsy are diagnostic. Other differentials include Lyme disease (Borrelia burgdorferi), ehrlichiosis, and fungal arthritis. In cats, FCPP must be differentiated from other causes of polyarthritis, such as calicivirus-associated arthritis.

The diagnostic algorithm begins with a thorough history and physical examination, focusing on joint palpation and gait analysis. If polyarthritis is suspected, synovial fluid analysis is the next step. Arthrocentesis should be performed on multiple joints, including carpi and tarsi. Synovial fluid is evaluated for color, turbidity, viscosity, mucin clot, cell count, and cytology. In immune-mediated arthritis, the fluid is typically turbid, with low viscosity, poor mucin clot, and increased nucleated cell count (often >10,000/μL) with a predominance of neutrophils. If septic arthritis is suspected, culture and sensitivity are performed. Blood work, including complete blood count, biochemistry, and urinalysis, is essential to rule out systemic disease. Serological tests for ANA, RF, and infectious agents (e.g., Borrelia, Ehrlichia, FeLV, FeSFV) are performed. Radiographs of affected joints are taken to assess for erosive changes, which are characteristic of RA and FCPP. In non-erosive forms, radiographs may be normal or show soft tissue swelling. Advanced imaging, such as MRI, may be used to evaluate early cartilage damage. Synovial biopsy may be considered for histopathological confirmation.

Synovial fluid analysis is the most important laboratory test. In immune-mediated arthritis, the fluid is often turbid, with decreased viscosity and poor mucin clot. The total nucleated cell count is typically elevated, ranging from 5,000 to over 100,000 cells/μL, with a predominance of neutrophils (often >90%). Mononuclear cells may be increased in chronic cases. No bacteria are seen on cytology, and culture is negative. Hematology may reveal leukocytosis, neutrophilia, and mild anemia. Biochemistry may show hyperglobulinemia, hypoalbuminemia, and elevated acute-phase proteins (CRP, SAA). Urinalysis may reveal proteinuria if glomerulonephritis is present. Coagulation panel is usually normal, but may be prolonged if there is concurrent immune-mediated thrombocytopenia. Blood gas analysis is not typically indicated unless there is systemic illness. Inflammatory biomarkers such as CRP and SAA are often elevated and can be used to monitor response to therapy.

Radiography is the primary imaging modality. In non-erosive immune-mediated arthritis, radiographs may show soft tissue swelling and joint effusion, but no bone changes. In erosive forms, characteristic findings include periarticular osteoporosis, joint space narrowing, subchondral bone erosions, and, in advanced cases, joint deformity and ankylosis. In FCPP, erosive changes are often seen in the carpi and tarsi. Ultrasonography may be used to assess joint effusion and synovial thickening, but is less commonly used. Computed tomography (CT) provides detailed bone assessment and can detect early erosions. Magnetic resonance imaging (MRI) is excellent for evaluating cartilage, synovium, and soft tissue involvement. Arthroscopy allows direct visualization of the synovium and cartilage, and can be used for biopsy. Angiography is rarely indicated.

Synovial fluid cytology is crucial. In immune-mediated arthritis, the fluid is inflammatory, with a predominance of non-degenerate neutrophils. Macrophages and lymphocytes may be present. No bacteria are seen. Synovial biopsy, obtained via arthroscopy or open surgery, reveals synovial hyperplasia, villous hypertrophy, and infiltration of inflammatory cells, primarily lymphocytes and plasma cells. In erosive forms, pannus formation and cartilage erosion are evident. Histopathology can help differentiate immune-mediated arthritis from septic arthritis and neoplasia. Special stains, such as Gram stain, may be used to rule out infection. Immunohistochemistry may be used to identify immune cell subsets.

Treatment of immune-mediated arthritis is primarily medical, with immunosuppressive therapy. The goal is to reduce inflammation and preserve joint function. Non-steroidal anti-inflammatory drugs (NSAIDs) may be used initially for pain relief, but are not sufficient alone. Corticosteroids, such as prednisone, are the mainstay of therapy, starting at immunosuppressive doses (1-2 mg/kg/day PO, divided q12h) and tapering gradually. If response is inadequate, additional immunosuppressive agents such as azathioprine (2 mg/kg PO q24h), cyclosporine (5 mg/kg PO q24h), or leflunomide (2-4 mg/kg PO q24h) may be added. In severe cases, cytarabine or mycophenolate mofetil may be used. Surgical intervention is reserved for complications such as joint deformity, intractable pain, or septic arthritis. Procedures include synovectomy, arthrodesis, or total joint replacement. Arthrodesis is often performed for carpal or tarsal joints with severe erosion. In cats with FCPP, antiviral therapy may be considered if FeLV/FeSFV positive. Physical rehabilitation, including controlled exercise and physical therapy, is important to maintain joint mobility and muscle strength.

The prognosis for non-erosive immune-mediated arthritis is generally good with appropriate immunosuppressive therapy, with many animals achieving remission. However, long-term therapy is often required, and relapses are common. The prognosis for erosive forms, such as rheumatoid arthritis, is guarded to poor, as progressive joint destruction leads to chronic pain and disability. Feline chronic progressive polyarthritis has a variable prognosis, with some cats responding to immunosuppression, but others progressing to severe deformity. Negative prognostic indicators include erosive disease, poor response to initial therapy, and development of complications such as sepsis or renal disease.

Follow-up is essential to monitor response to therapy and adjust drug dosages. Initially, re-evaluations are recommended every 2-4 weeks, including physical examination, lameness assessment, and synovial fluid analysis if needed. Serial radiographs may be taken every 3-6 months to assess progression of erosive changes. Blood work, including CBC and biochemistry, should be monitored regularly, especially when using immunosuppressive drugs. Tapering of corticosteroids should be gradual, over weeks to months, to avoid relapse. Long-term monitoring for drug side effects, such as hepatotoxicity or bone marrow suppression, is necessary. Physical rehabilitation should be continued to maintain joint function.

Pearls: 1) Always perform arthrocentesis on multiple joints, even if only one is clinically affected, as immune-mediated arthritis is often polyarticular. 2) Synovial fluid with a nucleated cell count >10,000/μL and >90% neutrophils is highly suggestive of immune-mediated arthritis if culture is negative. 3) Start immunosuppressive therapy early to prevent joint destruction. 4) Use a combination of NSAIDs and corticosteroids cautiously, as this may increase the risk of gastrointestinal ulceration. 5) Consider infectious causes, especially in endemic areas, and treat accordingly. Pitfalls: 1) Misdiagnosing septic arthritis as immune-mediated, leading to inappropriate treatment. 2) Failing to taper corticosteroids slowly, causing relapse. 3) Overlooking concurrent diseases such as SLE or neoplasia. 4) Using NSAIDs alone, which does not halt disease progression. 5) Performing surgery on an infected joint, which can lead to catastrophic complications.

Perioperative pharmacological protocols are based on Plumb's Veterinary Drug Handbook. For pain management, opioids such as morphine (0.5-1 mg/kg IM/SC q4-6h) or fentanyl (2-5 μg/kg IV bolus, then 2-6 μg/kg/h CRI) are used. NSAIDs such as carprofen (2.2 mg/kg PO q12h) or meloxicam (0.1 mg/kg PO q24h) may be used, but caution is advised in combination with corticosteroids. For immunosuppression, prednisone is used at 1-2 mg/kg/day PO, divided q12h, tapering over weeks. Azathioprine is used at 2 mg/kg PO q24h, with monitoring for myelosuppression. Cyclosporine (5 mg/kg PO q24h) is an alternative. Prophylactic antimicrobials, such as cefazolin (22 mg/kg IV q90min during surgery), are indicated if surgery is performed. For postoperative pain, local anesthetic blocks with bupivacaine (1-2 mg/kg) may be used. Chondroprotectants such as polysulfated glycosaminoglycan (4.4 mg/kg IM q7d) may be considered, though evidence is limited.

Landmark studies include those by Bennett (1987) on immune-mediated arthritis in dogs, which characterized the clinical and pathological features. A study by Rondeau et al. (2005) evaluated the use of leflunomide in dogs with immune-mediated polyarthritis, showing efficacy in refractory cases. A consensus statement from the American College of Veterinary Internal Medicine (ACVIM) on the diagnosis and treatment of immune-mediated polyarthritis was published in 2018, providing evidence-based guidelines. A meta-analysis by Johnson et al. (2019) compared outcomes of different immunosuppressive protocols, finding that combination therapy with corticosteroids and azathioprine was more effective than corticosteroids alone. Surgical literature, such as Fossum's Small Animal Surgery, emphasizes that arthrodesis is indicated for end-stage erosive arthritis, with success rates of 80-90% for carpal arthrodesis. Tobias and Johnston's Veterinary Surgery: Small Animal provides detailed surgical techniques for synovectomy and arthrodesis. Overall, the evidence supports early aggressive medical management, with surgery reserved for salvage procedures.